Gilead Sciences has agreed to sell its aldehyde dehydrogenase 2 (ALDH2) inhibitor, a drug candidate with the potential to treat behavior and substance addictions, to Amygdala Neurosciences, a Palo Alto, California-based biopharmaceutical company focused on addiction disorders.

The ALDH2 inhibitor drug candidate, GS-6637, is a Phase-II ready compound that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine, according to Amygdala. The drug has the potential to be used as a pharmacotherapy for substance and behavior-based addictions. Financial terms of the transaction were not disclosed.

Source: Amygdala Neurosciences